Tomasz Litwin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8459817/publications.pdf

Version: 2024-02-01

102	3,446	159358	161609
papers	citations	30 h-index	54 g-index

106	106	106	2969
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Wilson disease. Nature Reviews Disease Primers, 2018, 4, 21.	18.1	466
2	The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases. Journal of Trace Elements in Medicine and Biology, 2015, 31, 193-203.	1.5	194
3	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurology, The, 2018, 17, 1053-1060.	4.9	146
4	Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clinical Genetics, 2005, 68, 524-532.	1.0	124
5	Gender differences in Wilson's disease. Journal of the Neurological Sciences, 2012, 312, 31-35.	0.3	119
6	Early neurological worsening in patients with Wilson's disease. Journal of the Neurological Sciences, 2015, 355, 162-167.	0.3	116
7	Dâ€penicillamine versus zinc sulfate as firstâ€line therapy for Wilson's disease. European Journal of Neurology, 2014, 21, 599-606.	1.7	113
8	Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 2004, 4, 1307-1318.	1.7	106
9	Wilsonâ€™s diseaseâ€”cause of mortality in 164 patients during 1992â€“2003 observation period. Journal of Neurology, 2005, 252, 698-703.	1.8	89
10	Brain metal accumulation in Wilson's disease. Journal of the Neurological Sciences, 2013, 329, 55-58.	0.3	77
11	Wilson Disease and Other Neurodegenerations with Metal Accumulations. Neurologic Clinics, 2015, 33, 175-204.	0.8	76
12	Compliant treatment with antiâ€copper agents prevents clinically overt <scp>W</scp>ilson's disease in preâ€symptomatic patients. European Journal of Neurology, 2014, 21, 332-337.	1.7	70
13	p.H1069Q mutation inATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Movement Disorders, 2006, 21, 245-248.	2.2	68
14	Psychiatric manifestations in Wilsonâ€™s disease: possibilities and difficulties for treatment. Therapeutic Advances in Psychopharmacology, 2018, 8, 199-211.	1.2	68
15	New approach to the rehabilitation of post-stroke focal cognitive syndrome: Effect of levodopa combined with speech and language therapy on functional recovery from aphasia. Journal of the Neurological Sciences, 2009, 283, 214-218.	0.3	61
16	Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI â€“ histopathological study. Neuropathology and Applied Neurobiology, 2017, 43, 514-532.	1.8	60
17	Neurologic impairment in Wilson disease. Annals of Translational Medicine, 2019, 7, S64-S64.	0.7	58
18	Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 101-119.	1.0	52

#	Article	IF	Citations
19	Wilson disease â€“ currently used anticopper therapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 181-191.	1.0	47
20	Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilsonâ€™s Disease Rating Scale. BMC Neurology, 2018, 18, 34.	0.8	43
21	Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study. Movement Disorders, 2020, 35, 994-1001.	2.2	43
22	Apolipoprotein E gene (APOE) genotype in Wilsonâ€™s disease: Impact on clinical presentation. Parkinsonism and Related Disorders, 2012, 18, 367-369.	1.1	42
23	The effect of gender on brain MRI pathology in Wilsonâ€™s disease. Metabolic Brain Disease, 2013, 28, 69-75.	1.4	42
24	Symptomatic treatment of neurologic symptoms in Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 211-223.	1.0	39
25	Wholeâ€exome sequencing identifies novel pathogenic variants across the ATP7B gene and some modifiers of Wilson's disease phenotype. Liver International, 2019, 39, 177-186.	1.9	38
26	Clinical manifestations of Wilson disease in organs other than the liver and brain. Annals of Translational Medicine, 2019, 7, S62-S62.	0.7	38
27	Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilsonâ€™s disease.. Neuropsychology, 2015, 29, 25-30.	1.0	34
28	Wilson diseaseâ€”treatment perspectives. Annals of Translational Medicine, 2019, 7, S68-S68.	0.7	34
29	Symptomatic copper deficiency in three Wilson's disease patients treated with zinc sulphate. Neurologia I Neurochirurgia Polska, 2014, 48, 214-218.	0.6	32
30	Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers. Epigenetics and Chromatin, 2019, 12, 10.	1.8	32
31	Encephalopathy in Wilson Disease: Copper Toxicity or Liver Failure?. Journal of Clinical and Experimental Hepatology, 2015, 5, S88-S95.	0.4	31
32	The sunflower cataract in Wilsonâ€™s disease: pathognomonic sign or rare finding?. Acta Neurologica Belgica, 2016, 116, 325-328.	0.5	31
33	Persistence with treatment for Wilson disease: a retrospective study. BMC Neurology, 2019, 19, 278.	0.8	30
34	Neurological presentation of Wilson's disease in a patient after liver transplantation. Movement Disorders, 2008, 23, 743-746.	2.2	29
35	Other organ involvement and clinical aspects of Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 157-169.	1.0	28
36	Does brain degeneration in Wilson disease involve not only copper but also iron accumulation?. Neurologia I Neurochirurgia Polska, 2013, 47, 542-546.	0.6	27

#	Article	IF	Citations
37	Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. Acta Neurologica Scandinavica, 2014, 130, 305-311.	1.0	27
38	Brain volume is related to neurological impairment and to copper overload in Wilsonâ€™s disease. Neurological Sciences, 2019, 40, 2089-2095.	0.9	27
39	Optical coherence tomography and electrophysiology of retinal and visual pathways in Wilsonâ€™s disease. Metabolic Brain Disease, 2016, 31, 405-415.	1.4	26
40	Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver International, 2018, 38, 1860-1866.	1.9	26
41	Lenticular nucleus hyperechogenicity in Wilsonâ€™s disease reflects local copper, but not iron accumulation. Journal of Neural Transmission, 2014, 121, 1273-1279.	1.4	24
42	Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod. Neurologia I Neurochirurgia Polska, 2017, 51, 156-162.	0.6	24
43	Association of Dopamine Receptor Gene Polymorphisms with the Clinical Course of Wilson Disease. JIMD Reports, 2012, 8, 73-80.	0.7	23
44	Concordance rates of Wilson's disease phenotype among siblings. Journal of Inherited Metabolic Disease, 2014, 37, 131-135.	1.7	22
45	Optical coherence tomography as a marker of neurodegeneration in patients with Wilsonâ€™s disease. Acta Neurologica Belgica, 2017, 117, 867-871.	0.5	22
46	Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes. International Journal of Molecular Sciences, 2019, 20, 5937.	1.8	22
47	Anterior segment optical coherence tomography (<scp>AS</scp>â€<scp>OCT</scp>) as a new method of detecting copper deposits forming the Kayserâ€“Fleischer ring in patients with Wilson disease. Acta Ophthalmologica, 2019, 97, e757-e760.	0.6	20
48	Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated. Emergency Medicine Journal, 2007, 24, 96-99.	0.4	19
49	Families with Wilson's disease in subsequent generations: Clinical and genetic analysis. Movement Disorders, 2014, 29, 1828-1832.	2.2	18
50	Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease. Human Molecular Genetics, 2018, 27, 3854-3869.	1.4	18
51	Acute focal dystonia induced by a tricyclic antidepressant in a patient with Wilson disease: a case report. Neurologia I Neurochirurgia Polska, 2013, 47, 502-506.	0.6	17
52	Gene variants encoding proteins involved in antioxidant defense system and the clinical expression of Wilson disease. Liver International, 2015, 35, 215-222.	1.9	17
53	Cardiac assessment in Wilsonâ€™s disease patients based on electrocardiography and echocardiography examination. Archives of Medical Science, 2019, 15, 857-864.	0.4	17
54	Intravenous thrombolysis for acute ischaemic stroke in patients not fully adhering to the European licence in Poland. Neurologia I Neurochirurgia Polska, 2012, 46, 3-14.	0.6	16

#	Article	IF	Citations
55	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations. Movement Disorders, 2022, 37, 1074-1079.	2.2	16
56	Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinsonâ€™s disease. Neuroscience, 2005, 131, 247-254.	1.1	15
57	Treatment with d-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease. BioMetals, 2014, 27, 207-215.	1.8	15
58	MR image mimicking the â€œeye of the tigerâ€•sign in Wilsonâ€™s disease. Journal of Neurology, 2014, 261, 1025-1027.	1.8	15
59	Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. Functional Neurology, 2014, 29, 23-9.	1.3	15
60	Lithium Treatment of a Bipolar Patient with Wilson's Disease: A Case Report. Pharmacopsychiatry, 2013, 46, 120-121.	1.7	14
61	Neurological manifestations in Wilsonâ€™s disease â€“possible treatment options for symptoms. Expert Opinion on Orphan Drugs, 2016, 4, 719-728.	0.5	14
62	Evaluation of liver fibrosis in patients with Wilsonâ€™s disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 535-540.	0.8	14
63	Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilsonï¿½s disease. Functional Neurology, 2015, 30, 264-8.	1.3	14
64	Frequencies of initial gait disturbances and falls in 100 Wilson's disease patients. Gait and Posture, 2015, 42, 601-603.	0.6	13
65	Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurologia I Neurochirurgia Polska, 2013, 47, 393-397.	0.6	12
66	Psychiatric disturbances as a first clinical symptom of Wilsonâ€™s disease â€“ case report.. Psychiatria Polska, 2016, 50, 337-344.	0.2	12
67	Brain magnetic resonance imaging and severity of neurological disease in Wilsonâ€™s disease â€” the neuroradiological correlations. Neurological Sciences, 2022, 43, 4405-4412.	0.9	11
68	Sunflower cataract: do not forget Wilson's disease. Practical Neurology, 2015, 15, 385-386.	0.5	10
69	Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilsonâ€™s disease. BioMetals, 2021, 34, 407-414.	1.8	9
70	Cerebrovascular reactivity and disease activity in relapsing-remitting multiple sclerosis. Advances in Clinical and Experimental Medicine, 2020, 29, 183-188.	0.6	9
71	Influence of BDNF polymorphisms on Wilsonâ€™s disease susceptibility and clinical course. Metabolic Brain Disease, 2013, 28, 447-453.	1.4	8
72	Positivity of serum â€œclassicalâ€•onconeural antibodies in a series of 2063 consecutive patients with suspicion of paraneoplastic neurological syndrome. Journal of Neuroimmunology, 2013, 259, 75-80.	1.1	8

#	Article	IF	Citations
73	Substantial disease exacerbation in a patient with relapsing-remitting multiple sclerosis after withdrawal from siponimod. Neurologia I Neurochirurgia Polska, 2018, 52, 98-101.	0.6	8
74	Social and demographic characteristics of a Polish cohort with Wilson disease and the impact of treatment persistence. Orphanet Journal of Rare Diseases, 2019, 14, 167.	1.2	8
75	Difficulties in diagnosis and treatment of Wilson diseaseâ€"a case series of five patients. Annals of Translational Medicine, 2019, 7, S73-S73.	0.7	8
76	Pitfalls in diagnosing Wilsonâ€™s Disease by genetic testing alone: the case of a 47-year-old woman with two pathogenic variants of the ATP7B gene. Neurologia I Neurochirurgia Polska, 2020, 54, 478-480.	0.6	8
77	Liver transplantation as a treatment for Wilsonâ€™s disease with neurological presentation: a systematic literature review. Acta Neurologica Belgica, 2022, 122, 505-518.	0.5	8
78	Gastropathy in patients with Wilson disease. Scandinavian Journal of Gastroenterology, 2020, 55, 14-17.	0.6	7
79	mtDNA depletionâ€like syndrome in Wilson disease. Liver International, 2020, 40, 2776-2787.	1.9	7
80	Wilsonâ€™s disease- management and long term outcomes. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, 56-57, 101768.	1.0	7
81	Diagnosis of Wilson Disease and Its Phenotypes by Using Artificial Intelligence. Biomolecules, 2021, 11, 1243.	1.8	6
82	Wilson's disease: does iron metabolism impact phenotypic presentation?. Liver International, 2012, 32, 869-870.	1.9	5
83	Treatment of Wilsonâ€™s disease â€“ another point of view. Expert Opinion on Orphan Drugs, 2015, 3, 239-243.	0.5	5
84	Difference in iron metabolism may partly explain sex-related variability in the manifestation of Wilsonâ€™s disease. Journal of Trace Elements in Medicine and Biology, 2020, 62, 126637.	1.5	5
85	Multiple sclerosis in two patients with coexisting Wilson's disease. Multiple Sclerosis and Related Disorders, 2014, 3, 387-390.	0.9	4
86	Oral Chelator Treatment of Wilson Disease. , 2019, , 357-364.		4
87	Do silent infarcts modify the effect of thrombolysis for stroke?. Acta Neurologica Scandinavica, 2013, 127, 227-232.	1.0	3
88	Effect of homeostatic iron regulator protein gene mutation on Wilson's disease clinical manifestation: original data and literature review. International Journal of Neuroscience, 2022, 132, 894-900.	0.8	3
89	Is there heart disease in cases of neurodegeneration associated with mutations in C19orf12?. Parkinsonism and Related Disorders, 2020, 80, 15-18.	1.1	3
90	Transcranial sonography changes in heterozygotic carriers of the ATP7B gene. Neurological Sciences, 2020, 41, 2605-2612.	0.9	3

#	Article	IF	Citations
91	Sleep disturbances in newly diagnosed treatment-naÃ¯ve patients with Wilsonâ€™s disease. Acta Neurologica Belgica, 2022, 122, 745-751.	0.5	3
92	Treatment of Wilsonâ€™s disease â€“ an update. Expert Opinion on Orphan Drugs, 2019, 7, 287-294.	0.5	2
93	Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: a report of the first 100 cases. Neurologia I Neurochirurgia Polska, 2008, 42, 1-5.	0.6	2
94	Assessment of brain cortical atrophy in neurodegenerative as well as selected neurological disorders â€“ assessment methods and significance in diagnosis. Neuropsychiatria I Neuropsychologia, 2017, 1, 20-29.	0.3	1
95	Neurological Wilson Disease. , 2019, , 145-157.		1
96	Motor Evoked Potentials in Newly Diagnosed and Treated Patients With Wilson Disease. Journal of Clinical Neurophysiology, 2021, Publish Ahead of Print, .	0.9	1
97	Blink reflex in newly diagnosed and treated patients with Wilsonâ€™s disease. Journal of Neural Transmission, 2021, 128, 1873-1880.	1.4	1
98	Disorders resulting from transporter defects. , 2016, , 687-693.		0
99	Non-paraneoplastic variant of limbic encephalitis â€“ case report. Postepy Psychiatrii I Neurologii, 2017, 26, 255-269.	0.2	0
100	Transcranial sonography changes in patients with Wilsonâ€™s Disease during de-coppering therapy. Neurologia I Neurochirurgia Polska, 2020, 54, 185-192.	0.6	0
101	Perspectives of Wilsonâ€™s disease treatment. Pharmacotherapy in Psychiatry and Neurology, 2021, 37, .	0.1	0
102	Liver injury in Wilson's disease: An immunohistochemical study. Advances in Medical Sciences, 2022, 67, 203-207.	0.9	0